Heart Failure Stocks List
|SENS||D||Sensyne Health Plc||0.00|
|HLTH||C||SPDR® MSCI Europe Health Care UCITS ETF||9.25|
|VUKE||F||Vanguard FTSE 100 UCITS ETF||5.76|
|UC64||A||UBS MSCI United Kingdom UCITS ETF||5.68|
|CSUK||A||iShares MSCI UK UCITS ETF||5.49|
|XDUK||A||db x-trackers FTSE 100 UCITS ETF||5.45|
View all Heart Failure related ETFs...
|2021-05-06||BVXP||Crossed Above 50 DMA||Bullish|
|2021-05-06||BVXP||200 DMA Resistance||Bearish|
|2021-05-06||BVXP||Narrow Range Bar||Range Contraction|
|2021-05-06||BVXP||Stochastic Reached Overbought||Strength|
|2021-05-06||NSCI||Fell Below 50 DMA||Bearish|
|2021-05-06||SENS||20 DMA Resistance||Bearish|
|2021-05-06||SENS||Cup with Handle||Other|
Heart failure (HF), also known as chronic heart failure (CHF), is when the heart is unable to pump sufficiently to maintain blood flow to meet the body's needs. Signs and symptoms of heart failure commonly include shortness of breath, excessive tiredness, and leg swelling. The shortness of breath is usually worse with exercise, while lying down, and may wake the person at night. A limited ability to exercise is also a common feature. Chest pain, including angina, does not typically occur due to heart failure.Common causes of heart failure include coronary artery disease including a previous myocardial infarction (heart attack), high blood pressure, atrial fibrillation, valvular heart disease, excess alcohol use, infection, and cardiomyopathy of an unknown cause. These cause heart failure by changing either the structure or the functioning of the heart. The two types of heart failure - heart failure with reduced ejection fraction (HFrEF), and heart failure with preserved ejection fraction (HFpEF) - are based on whether the ability of the left ventricle to contract is affected, or the heart's ability to relax. The severity of disease is graded by the severity of symptoms with exercise. Heart failure is not the same as myocardial infarction (in which part of the heart muscle dies) or cardiac arrest (in which blood flow stops altogether). Other diseases that may have symptoms similar to heart failure include obesity, kidney failure, liver problems, anemia, and thyroid disease. Heart failure is diagnosed based on the history of the symptoms and a physical examination, with confirmation by echocardiography. Blood tests, electrocardiography, and chest radiography may be useful to determine the underlying cause.Treatment depends on the severity and cause of the disease. In people with chronic stable mild heart failure, treatment commonly consists of lifestyle modifications such as stopping smoking, physical exercise, and dietary changes, as well as medications. In those with heart failure due to left ventricular dysfunction, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, or valsartan/sacubitril along with beta blockers are recommended. For those with severe disease, aldosterone antagonists, or hydralazine with a nitrate may be used. Diuretics are useful for preventing fluid retention and the resulting shortness of breath. Sometimes, depending on the cause, an implanted device such as a pacemaker or an implantable cardiac defibrillator (ICD) may be recommended. In some moderate or severe cases, cardiac resynchronization therapy (CRT) or cardiac contractility modulation may be of benefit. A ventricular assist device or occasionally a heart transplant may be recommended in those with severe disease that persists despite all other measures.Heart failure is a common, costly, and potentially fatal condition. In 2015 it affected about 40 million people globally. Overall around 2% of adults have heart failure and in those over the age of 65, this increases to 6–10%. Rates are predicted to increase. The risk of death is about 35% the first year after diagnosis; while by the second year the risk of death is less than 10% for those who remain alive. This degree of risk of death is similar to some cancers. In the United Kingdom, the disease is the reason for 5% of emergency hospital admissions. Heart failure has been known since ancient times with the Ebers papyrus commenting on it around 1550 BCE.